
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
FDA's latest proposal focuses on electronic health systems for filing drug labeling information and facility and product data.
over 22 years ago
Stable Isotopic Characterization of Analgesic Drugsover 22 years ago
August 2004over 22 years ago
Increased Outsourcing Driving Investments in CRO Industryover 22 years ago
In the Spotlight-August 2004over 22 years ago
Interphex Delivers Packaging Solutionsover 22 years ago
Vapor-Phase Hydrogen Peroxide Resistance of Environmental Isolatesover 22 years ago
Decoding the US Pharmacopeia





